Haemonetics (NYSE:HAE) Hits New 52-Week Low - What's Next?

Key Points

• Haemonetics shares reached a new 52-week low, trading at $50.53 before closing at $50.93 amidst a volume of 46,401 shares.
• Analyst ratings for Haemonetics exhibit a generally positive outlook, with one Strong Buy and seven Buy ratings, despite varying target prices from multiple firms, the consensus being $78.78.
• The company reported better-than-expected earnings of $1.10 per share for the last quarter, surpassing analyst expectations and achieving a revenue of $321.39 million.

Haemonetics Corporation (NYSE:HAE - Get Free Report) hit a new 52-week low on Tuesday . The stock traded as low as $50.53 and last traded at $50.93, with a volume of 46401 shares changing hands. The stock had previously closed at $51.35.

Analyst Ratings Changes

HAE has been the topic of several analyst reports. Raymond James Financial lowered shares of Haemonetics from a "strong-buy" rating to an "outperform" rating and cut their price objective for the company from $105.00 to $78.00 in a report on Monday, August 11th. Citigroup upgraded shares of Haemonetics from a "neutral" rating to a "buy" rating and set a $90.00 price objective on the stock in a report on Wednesday, July 9th. Barrington Research cut their price objective on shares of Haemonetics from $95.00 to $86.00 and set an "outperform" rating on the stock in a report on Friday, August 8th. Needham & Company LLC restated a "buy" rating and issued a $68.00 price objective (down from $84.00) on shares of Haemonetics in a report on Thursday, August 7th. Finally, Robert W. Baird initiated coverage on shares of Haemonetics in a report on Thursday, June 26th. They issued an "outperform" rating and a $87.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $78.78.

Haemonetics Trading Down 1.2%

The stock has a market cap of $2.43 billion, a price-to-earnings ratio of 15.45, a PEG ratio of 0.94 and a beta of 0.39. The company has a quick ratio of 1.04, a current ratio of 1.72 and a debt-to-equity ratio of 1.04. The business's 50 day simple moving average is $61.19 and its 200 day simple moving average is $64.88.

Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share for the quarter, topping the consensus estimate of $1.01 by $0.09. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The business had revenue of $321.39 million during the quarter, compared to analysts' expectations of $305.12 million. During the same quarter in the previous year, the company earned $1.02 EPS. The business's revenue was down 4.4% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. On average, research analysts expect that Haemonetics Corporation will post 4.55 EPS for the current fiscal year.

Institutional Investors Weigh In On Haemonetics

Institutional investors have recently added to or reduced their stakes in the business. Dynamic Technology Lab Private Ltd bought a new stake in Haemonetics during the 1st quarter worth approximately $468,000. AQR Capital Management LLC grew its holdings in Haemonetics by 591.6% during the 1st quarter. AQR Capital Management LLC now owns 174,565 shares of the medical instruments supplier's stock worth $10,931,000 after acquiring an additional 149,325 shares during the last quarter. Envestnet Asset Management Inc. grew its holdings in Haemonetics by 16.0% during the 1st quarter. Envestnet Asset Management Inc. now owns 55,746 shares of the medical instruments supplier's stock worth $3,543,000 after acquiring an additional 7,678 shares during the last quarter. Royal Bank of Canada grew its holdings in Haemonetics by 2.3% during the 1st quarter. Royal Bank of Canada now owns 1,075,604 shares of the medical instruments supplier's stock worth $68,355,000 after acquiring an additional 24,650 shares during the last quarter. Finally, GAMMA Investing LLC grew its holdings in Haemonetics by 11,225.0% during the 1st quarter. GAMMA Investing LLC now owns 17,667 shares of the medical instruments supplier's stock worth $11,230,000 after acquiring an additional 17,511 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.